Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

http://www.wikidata.org/entity/Q43204477

about

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than Ritonavir A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Recent key advances in human immunodeficiency virus medicine and implications for China Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Clinical management of HIV drug resistance.Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism Antiretroviral drugs: critical issues and recent advances Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance Biotransformation of Cobicistat: Metabolic Pathways and Enzymes Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.Recent advances in antiretroviral drugs.Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?The successes and failures of HIV drug discovery.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.Safety of pharmacoenhancers for HIV therapy.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.Cobicistat : a new opportunity in the treatment of HIV disease?Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Pharmacokinetic enhancers in HIV therapeutics.Darunavir/cobicistat once daily for the treatment of HIV.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Renal effects of novel antiretroviral drugs.

P2860

Q24633870-4012A353-336B-414F-A208-E360A840E4B0 Q26750406-DFDCD45D-D38C-4E2D-9D85-0DF040CFCCC7 Q26771182-C3B1BF5F-AAC5-4C67-8422-7340A9DEA0D5 Q26777251-65E79A7C-C524-4836-B942-B423DE038E44 Q27677369-B34B5AEC-C6F6-4C25-8074-E1307C039E32 Q27692040-219F1A80-07A6-4BCA-B3D1-B7A67C59472B Q28073206-0179DE41-45F7-4EC0-9936-5826D193CABF Q33680234-D2A866A1-DEA8-4086-B620-6D2D3F921161 Q33933502-898D1FAF-3039-42B6-8D48-DA18127F727D Q34634156-70FE1359-3E0E-4EE9-B31F-09ED6C6B7E93 Q34976284-A496B4D9-FF81-49EF-99DF-296DB2CF104A Q35023687-7219E5DF-8CA0-4379-BA3C-3BD303D69445 Q35261045-52A7F5D1-EB8F-4B89-850D-A0627994B59F Q35933538-D179ECD8-D453-483E-83EF-6E5730936AF7 Q36020992-C0A4978A-47DF-4F25-ABD8-A84C74571208 Q36072448-19E302C8-79CF-4A81-883B-C973AFA6CA3F Q36541070-18D81EF9-2C83-4586-979A-99C4547CA030 Q37207332-052446CD-45AF-496D-9D0A-5D9310453EB8 Q37335799-C1678629-73FF-4243-A223-B17D7980AD73 Q37696729-4E35B904-98ED-4FBC-AB79-CAFD3A8053C3 Q37713076-A55A3501-66B6-4185-AC9C-2EF7ADF26C62 Q37779092-E5B269F2-9824-4A44-B7B2-E3F99B6D798E Q37818237-4622F2DE-F83D-4C64-BA09-9CADCBDB755F Q37850890-9DC61395-BA68-45BE-9B1B-A2D9E914E97B Q38009758-4EB13A63-EEDA-4FAC-83F0-AB322A77270B Q38014557-5FF89085-994E-421A-8133-D91E1561C30A Q38030981-9A077E70-24EA-4EC6-BFCD-26A869FFF28A Q38057371-58BACE97-1DAA-4981-AEC4-8548A976A306 Q38058501-CF7DA121-7E80-4788-8847-17073A8D48D9 Q38087555-D5F9029F-183B-4937-B612-CE54DA997650 Q38109095-950B0800-4EA7-4CA6-B490-E45938BA376D Q38171345-DAB19072-D6E1-41C5-A6B4-3F5D1ED3871E Q38171753-D4A60865-FA5E-4CB2-AD02-731C3C9F6E64 Q38211165-FA7CBCC5-A279-4F10-BDA7-ED3636E35EDA Q38222092-6C96A462-DB88-41E0-97C5-D5F7433F97F2 Q38244014-6A7A98C0-64B9-4C31-B171-60DD213701E8 Q38472696-139BB6E5-71DC-4BD5-A636-682FF13D05C1 Q38719799-CC88F865-A32B-4933-AF14-4A34DD8052AA Q38836056-78170BA1-29E9-415A-8B89-533EED3E93E3 Q38837077-2D505D6E-9156-4796-B67B-EE17D72C4199

P2860

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

http://www.wikidata.org/entity/Q43204477

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@en

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@nl

type

label

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@en

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@nl

prefLabel

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@en

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@nl

P1433

Q43204477-EACB0DE8-A73E-425F-9652-269EA6050C95

P1476

Q43204477-F6C8FBA8-D120-44E2-B32F-F23BF81318FF

P2093

Q43204477-4B814E22-E763-4F23-8BCC-40F4563A0D18

Q43204477-55688674-58B7-46C6-ACA2-99B249374A44

Q43204477-59880A7C-488A-4D93-A4B9-939A6EABA4E1

Q43204477-83AA9D4E-30AD-4767-A4AA-BA37F10A7B9E

Q43204477-8947B0FA-A2D3-421F-A5B6-BE3697E079D9

Q43204477-8A6D0DB6-6580-43B0-95C9-4FCDEC4182D5

Q43204477-939F51A9-63F4-498A-8D48-859EB5CF2B06

Q43204477-D29E05B8-2B7D-43D6-958B-F92360683A15

Q43204477-E2B6A894-EB9B-4ED0-9AEE-43F0472B8AA5

P2860

Q43204477-1DF0A379-CD2B-48AE-A69D-6CDB359FFDBE

Q43204477-292CAED3-DE95-4E69-96E4-006CC75A6AC6

Q43204477-39B97D95-F516-417C-AE60-242F1C122915

Q43204477-3F430003-64D2-46A0-AB6C-29319D38AFC6

Q43204477-3F5AD599-2EB9-4C65-AC5A-4731CABC8D80

Q43204477-4AF6CB3E-B0A9-490A-B21B-05C1F9ACE1FA

Q43204477-5E80C197-37AA-4BDA-B2B3-9DF02C5DC957

Q43204477-66605AE4-088C-4828-8C1B-395C7D6B449D

Q43204477-6B18D183-F342-4470-BF11-61123D9258E9

Q43204477-6CC28899-8ADD-4884-8692-AFD5655B47BC

P304

Q43204477-880C5B71-D8D0-4127-A928-5A6D02029CF2

P31

Q43204477-356E206F-B3C9-4B72-A36A-9BABF57D72EF

P356

Q43204477-87CA5954-8E8F-433E-94D3-921E11224994

P407

Q43204477-A3BA401A-B407-4F79-AB6E-A3C9592FAAB0

P433

Q43204477-E8A35817-5FE6-4D3F-B260-D350BD36180E

P478

Q43204477-0718781F-3CDD-4D5A-A785-A5EB8B4D1538

P577

Q43204477-ED9185A9-1A63-41F5-B369-184905EEAB62

P5875

Q43204477-AD71C995-20CB-44D0-9EE2-9ABE2CF0CBB3

P698

Q43204477-5346814D-B006-4E57-A5C0-0932E0DEDE12

P921

Q43204477-92D5FFCF-6474-4028-ADAD-A0E5278B94FF

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Pharmacokinetics and pharmacod ...... cer without anti-HIV activity.

@en

P2093

A A Mathias

http://www.w3.org/2001/XMLSchema#string

A Jain

http://www.w3.org/2001/XMLSchema#string

B P Kearney

http://www.w3.org/2001/XMLSchema#string

B P Murray

http://www.w3.org/2001/XMLSchema#string

D Warren

http://www.w3.org/2001/XMLSchema#string

J Hui

http://www.w3.org/2001/XMLSchema#string

L Wei

http://www.w3.org/2001/XMLSchema#string

P German

http://www.w3.org/2001/XMLSchema#string

S West

http://www.w3.org/2001/XMLSchema#string

P2860

Can the pharmaceutical industry reduce attrition rates?

Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients

Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.

Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

P304

322-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2009.228

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40819963

http://www.w3.org/2001/XMLSchema#string

P698

20043009

http://www.w3.org/2001/XMLSchema#string

P921